All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Characteristics associated with response in patients with R/R CLL/SLL treated with liso-cel: TRANSCEND-CLL-004 post hoc analysis
|
The phase I/II TRANSCEND-CLL-004 trial (NCT03331198) assessed the safety and efficacy of liso-cel in adult patients with R/R CLL/SLL.1 The primary results from this trial were previously reported by the Lymphoma Hub. Briefly, the ORR and CR/CRi rates at DL2 were 47% and 18%, respectively. Based on results from this trial, liso-cel was approved by the FDA for the treatment of adult patients with R/R CLL/SLL who received ≥2 prior lines of therapy, including a BTKi and a BCL-2 inhibitor. A post hoc analysis of this trial assessed the correlations between patient characteristics and efficacy response and safety in patients treated at DL2 (n = 87). Results from this analysis were presented at the SOHO 2024 Annual Meeting by Wierda.1
|
| Key learnings: |
|
ORR and CRR were similar in patients with or without high-risk disease features at baseline, including unmutated IGHV (ORR, 41.5% vs 63.2%; CRR , 22.0% vs 21.1%), del(17p) (ORR, 47.1% vs 45.1%; CRR, 26.5% vs 13.7%), TP53 mutation (ORR, 41.7% vs 50.0%; CRR, 22.2% vs 16.0%), del(17p) and TP53 mutation (ORR, 44.0% vs 46.7%; CRR, 28.0% vs 15.0%), and complex karyotype (ORR, 44.2% vs 52.9%; CRR, 19.2% vs 17.6%). |
|
Patients with fewer prior lines of treatment and lower baseline tumor burden showed improved response rates; the ORRs for patients with ≤3 prior lines of therapy vs >3 prior lines of therapy were 54.5% vs 44.6%, and for patients without bulky (≥5 cm) disease vs with bulky disease were 63.2% vs 31.7%. |
|
Inflammatory markers, bulky disease, and lower estimated CrCl rates may be associated with a higher risk of neurological events. |
|
These findings highlight the benefit of liso-cel in patients with R/R CLL/SLL, regardless of high-risk disease features, and suggest that patients treated in earlier lines of therapy with a lower tumor burden may have improved outcomes. |
Abbreviations: BCL-2, B-cell lymphoma 2; BTKi, Bruton tyrosine kinase inhibitor; DL, dose level; FDA, U.S. Food and Drug Administration; IGHV, immunoglobulin heavy chain gene; CI, confidence interval; CLL, chronic lymphocytic leukemia; CrCl, creatinine clearance; CRi, CR with incomplete blood count recovery; CRR, complete response rate; liso-cel; lisocabtagene maraleucel; OR, odds ratio; ORR, overall response rate; R/R, relapsed/refractory; SLL, small lymphocytic lymphoma; SOHO, Society of Hematologic Oncology.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?
